Ambrx Biopharma Beheer
Beheer criteriumcontroles 1/4
Ambrx Biopharma's CEO is Dan O'Connor, appointed in Nov 2022, has a tenure of 1.33 years. total yearly compensation is $1.03M, comprised of 6.7% salary and 93.3% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth $1.35M. The average tenure of the management team and the board of directors is 1.1 years and 1.5 years respectively.
Belangrijke informatie
Dan O'Connor
Algemeen directeur
US$1.0m
Totale compensatie
| Percentage CEO-salaris | 6.7% |
| Dienstverband CEO | 1.3yrs |
| Eigendom CEO | 0.08% |
| Management gemiddelde ambtstermijn | 1.1yrs |
| Gemiddelde ambtstermijn bestuur | 1.5yrs |
Recente managementupdates
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$60m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$1m | US$69k | -US$78m |
Compensatie versus markt: Dan's total compensation ($USD1.03M) is below average for companies of similar size in the US market ($USD4.96M).
Compensatie versus inkomsten: Insufficient data to compare Dan's compensation with company performance.
CEO
Dan O'Connor (58 yo)
1.3yrs
Tenure
US$1,034,168
Compensatie
Mr. Daniel J. O'Connor, J.D., also known as Dan, served as an Independent Director of ZyVersa Therapeutics, Inc. since December 13, 2022 until May 2023. He serves as President, CEO and Director of Ambrx Bi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.03m | 0.076% $ 1.3m | |
| Chief Financial Officer | 2.8yrs | US$1.73m | 0.036% $ 641.7k | |
| Chief Operating Officer | less than a year | geen gegevens | 0% $ 0 | |
| Chief Technology Officer | 2.2yrs | geen gegevens | geen gegevens | |
| Chief Scientific Officer & GM of China | 1.4yrs | geen gegevens | geen gegevens | |
| Senior VP | less than a year | geen gegevens | geen gegevens | |
| Vice President of Human Capital | less than a year | geen gegevens | geen gegevens | |
| Chief Clinical Officer | 1.1yrs | geen gegevens | geen gegevens | |
| Chief Regulatory Officer | less than a year | geen gegevens | geen gegevens |
1.1yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: AMAM's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.03m | 0.076% $ 1.3m | |
| Independent Director | 2.1yrs | US$268.55k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Chairman of the Board | less than a year | geen gegevens | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 1.7yrs | US$555.41k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 1.8yrs | US$156.12k | 0% $ 0 |
1.5yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: AMAM's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.